

ASX Announcement

7 January 2026

OncoSil Medical Receives a \$1.84 million R&D Tax Incentive Refund

Sydney, Australia – 7 January 2026: OncoSil Medical Limited (ASX: OSL) (“OncoSil” or “the Company”), a medical device company focused on localised treatments for patients with locally advanced pancreatic cancer (LAPC), today announces that it has received a **\$1.84 million** R&D tax incentive (RDTI) refund. This refund relates to eligible Australian and international research and development activities undertaken by the Company during the financial year ended 30 June 2025 (FY25).

The R&D Tax Incentive is an Australian Federal Government program that provides companies with cash incentives equal to 43.5% of eligible R&D expenditure, supporting innovation and investment in research.

Nigel Lange, CEO & Managing Director of OncoSil Medical, said: “Australia’s RDTI is a vital program that fosters innovation and enables companies like OncoSil to continue advancing our commercial-stage device. We are taking deliberate steps to unlock the potential of our treatment, with a strong focus on increasing clinician awareness and adoption of the OncoSil™ device, driving sales growth and creating shareholder value, in a fiscally responsible manner.”

Authorisation & Additional Information

This announcement was authorised by the Board of OncoSil Medical Limited.

For further information, please contact:

Mr. Nigel Lange CEO & Managing Director E: nigel.lange@oncosil.com T: +49 30 300 149 3043	Mr. Tim Luscombe & Mr. David Wood Joint Company Secretaries E: tim.luscombe@bio101.com david.wood@bio101.com T: +61 429 707 079 & +61 408 393 670	Ms. Julia Maguire The Capital Network Media and Investor Enquiries E: julia@thecapitalnetwork.com.au T: +61 2 7257 7338
--	--	---

About OncoSil Medical

OncoSil Medical (ASX:OSL) is a global medical device company focused on Interventional Oncology. OncoSil Medical’s mission is to improve the outcomes for people living with cancer by utilizing the selected and targeted intratumoural placement of Phosphorous-32 (32P) Microparticles in addition to chemotherapy.

OncoSil Medical has developed OncoSil™ device for the treatment of unresectable locally advanced pancreatic cancer. Its targeted approach enables healthcare professionals to deliver a greater radiation dose directly into the tumour compared to external beam radiotherapy, while sparing surrounding critical organs.

Pancreatic cancer is the 12th most common cancer in men and the 11th most common cancer in women across the globe, with 500,000 new cases detected every year¹. Since pancreatic cancer is generally diagnosed at a later stage, it has a poor prognosis for long-term survival.

OncoSil™ has received CE Marking approval, providing marketing authorisation in both the EU and the UK. OncoSil™ is designated as a breakthrough device in both Europe and the United States. It is currently approved for sale in 30+ countries including European Union,

United Kingdom, Turkey and Israel, with commercial treatments using the device already undertaken in Spain, Italy, Austria, Germany, Greece, Turkey, Portugal, Israel and the UK.

To learn more, please visit: www.oncosil.com/

1. <https://gco.iarc.fr/en>